Neoadjuvant Radiotherapy Combined With Toripalimab for Locally Advanced Head and Neck Squamous Cell Carcinoma

Exclusion Criteria

• •Pregnant or breastfeeding, or planning to become pregnant during the study period
• •Patients with active autoimmune diseases or immunodeficiency diseases, including but not limited to myasthenia gravis, interstitial pneumonia, enteritis, autoimmune hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, positive HIV test or a history of the above diseases, or a history of organ transplantation;
• •Receiving systemic immunosuppressive drugs within 2 weeks before starting study treatment, or anticipating the need for systemic immunosuppressive drugs during study treatment;
• •Received systemic immunostimulants (including but not limited to interferon or interleukin-2 \[IL-2\]) within 4 weeks before starting study treatment;
• •History of other malignant tumors within the past 5 years, except cured cervical carcinoma in situ, non-melanoma skin cancer, localized prostate cancer, ductal carcinoma in situ;
• •Serious cardiovascular disease, unstable arrhythmia, or unstable angina pectoris within 3 months before starting study treatment;
• •The subject has an active infection or infectious disease, or unexplained fever (body temperature \> 38.5℃) during screening and before the first dose;
• •Patients who have received therapeutic oral or intravenous antibiotics within 2 weeks prior to starting study treatment; patients receiving prophylactic antibiotic therapy (e.g., prophylaxis for urinary tract infection or chronic obstructive pulmonary - Untreated active hepatitis;
• •Receiving immunotherapy such as PD-1/L1 antibody or CTLA-4 antibody within 4 weeks before enrollment;
• •Received chemotherapy or targeted therapy within 4 weeks before enrollment;
• •The subject has participated in or completed other clinical trials within 4 weeks before enrollment;
• •Subjects may need to receive other anti-tumor therapy during the study;
• •Subjects may need to receive a vaccine during the study or within 4 weeks prior to enrollment.